RCS - Osler Diagnostics Ld - Osler Diagnostics Announces a Company Update

Siemens AGAnnouncement

21/03/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220321:nRSU3649Fa&default-theme=true

RNS Number : 3649F  Osler Diagnostics Limited  21 March 2022

Osler Diagnostics Announces a Company Update

 

·   Osler provides an update on its breakthrough product, the Osler Origin,
and on the Osler organisation

·   Osler has developed the Osler Origin - a 'portable lab' that can
provide lab-quality diagnostics to anyone, anywhere, at any time

·   Osler has built a world-class team and Board of Directors - augmented
today by Chris Smith and David Berry

·   Osler was formed out of the University of Oxford in 2017 and has raised
~$100m from leading investors

 

Oxford, UK - 21 March 2022: Osler Diagnostics ('Osler' or the 'Company') is
pleased to provide an update on its breakthrough product, the Osler Origin,
and to announce an update on the organisation, including the appointments
today of Chris Smith as Chairman of the Board of Directors, and David Berry as
Non-Executive Director.

 

The Osler Origin is a 'portable lab' that can provide lab-quality diagnostics
to anyone, anywhere, at any time. It consists of a handheld diagnostic
instrument, and series of single-use test cartridges, each testing for one or
multiple biomarkers, from a small blood sample. The system boasts a
comprehensive test menu, performs each test with high-performance, and is
portable, low-cost, quick, and easy-to-use.

 

The Osler Origin represents a step-change in portable diagnostics, going
beyond current solutions which typically test for only a handful of targets,
and do so with performance that is significantly inferior to the central
laboratory, therein preventing their widespread adoption.

 

Consequently, the Osler Origin will transform current healthcare by providing
lab-quality point-of-care testing in the ED, ICU, and other settings. The
Osler Origin will also help create a new healthcare paradigm by enabling fully
decentralised and user-centric testing in community settings, with the ability
to link up with other services such as telemedicine and electronic health
records - therein enabling anyone, anywhere, to access, understand, and act on
their health.

 

Osler has now delivered the Osler Origin, with its initial test cartridges,
and is undergoing comprehensive testing in advance of regulatory activities.
At the same time, the Company is building out the commercial and product
ecosystem to support rapid product deployment post-regulatory approvals.

 

Osler has built an experienced leadership team, led by Connor Campbell,
co-founder and CEO, and a strong Board of Directors which is Chaired by Chris
Smith, CEO of Ortho Clinical Diagnostics, and includes David Berry, Founder
and CEO of Valo Health, and General Partner at Flagship Pioneering; Jorg
Debatin, former CTO, CMO, and VP at GE Healthcare; Amber Salzman, former SVP
at GlaxoSmithKline; Peter George, founder and former CEO of Clinigen; Erich
Reinhardt, former CEO at Siemens Healthcare; and Andre Crawford-Brunt, former
Global Head of Equity Trading at Deutsche Bank.

 

Osler was formed out of the University of Oxford chemistry department in 2017,
following decades of research. The same department is famous for inventing the
portable electrochemical blood glucose sensor, which is considered by many to
be the most successful diagnostic in history, and which pioneered the
widespread use of portable diagnostics.

 

Osler is headquartered in Oxford, UK, operating in a 5,000 sq. ft.
purpose-built lab space. It has built a multidisciplinary team of
approximately 100 staff and raised ∼$100m in funding from leading investors.

 

Connor Campbell, co-founder and CEO of Osler, commented: "The Osler Origin
represents a step-change in diagnostics and has the potential to transform
global healthcare by enabling anyone, anywhere, to access, understand, and act
on their healthcare information."

About Osler

Osler is a UK-based diagnostics company whose purpose is to enable anyone,
anywhere, to access, understand, and act on their health, to live healthier,
happier, and longer lives.

 

Osler has developed the Osler Origin - a 'portable lab' that can provide
lab-quality diagnostics to anyone, anywhere, at any time. The Osler Origin
will offer a wide portfolio of diagnostic tests and serve all major healthcare
settings, globally.

 

Osler was formed out of the University of Oxford in 2017, following decades of
research from the same department that invented the portable electrochemical
blood glucose sensor.

 

The Company is headquartered in Oxford, UK, employs approximately 100 staff
and is backed by leading investors.

 

For more information, please visit www.oslerdiagnostics.com
(http://www.oslerdiagnostics.com)

 

Contacts

Consilium Strategic Communications
 Osler Diagnostics

                                                                Mary-Jane Elliott
 media@oslerdiagnostics.com (mailto:media@oslerdiagnostics.com)

                                                                + 44 7739 788 014

                                                                  osler@consilium-comms.com (mailto:osler@consilium-comms.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFFIVVIIFIF